Generates revenue by selling automated imaging systems that scan cell slides and detect abnormal cells for cancer and prenatal testing, and by selling annual service contracts plus hardware, software and application upgrades to the installed base.
Geographic Exposure
United States64.07%
Other countries (excluding United States, Asia and Israel)28.62%
Asia (excluding Israel)5.86%
Israel1.45%
Revenue Drivers
Cell scanning system sales and upgrades
automated slide scanning systems sold with hardware, software and application upgrades
CORE51.2%
Service and maintenance contracts
annual service and maintenance agreements covering installed scanning systems
CORE48.8%
End Markets
Large commercial laboratories
Specialized commercial laboratories
Hospital laboratories
Research customers
Specializations
FISH-based detection of blood and bone marrow cancerPrenatal genetic screening of amniotic fluid samplesHER2 breast cancer tissue testingALK lung cancer tissue testingBladder cancer detection in urine samplesCirculating tumor cell scanning and liquid biopsy development+2 more
